Clinical Trials Logo

Clinical Trial Summary

This study uses to suppress the growth of tumors, extend the patient's survival time and improve the quality of life as much as possible. Through the treatment, the patient is given the chance to undergo surgical resection, thereby more effectively prolonging the OS. Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR and exerting anti-angiogenic effects. Preclinical studies have shown that its antitumor effect is better than that of the similar drug PTK787. Phase II studies of hepatocellular carcinoma have initially demonstrated the effectiveness and safety of apatinib in the treatment of advanced HCC. TACE embolized tumor artery blood supply to inhibit tumor growth and shrink tumors. Based on the therapeutic potential of apatinib, and TACE in their respective tumors, we designed a prospective exploratory clinical study of this patient with advanced liver cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03511703
Study type Interventional
Source Guangxi Medical University
Contact
Status Not yet recruiting
Phase Phase 2
Start date May 1, 2018
Completion date June 30, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03222076 - Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) Phase 2
Active, not recruiting NCT01658878 - An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Phase 1/Phase 2
Not yet recruiting NCT03172559 - Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI) N/A
Recruiting NCT02854839 - A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma Phase 2
Recruiting NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT02809534 - A Study of Anlotinib in Patients With Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT02743065 - HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China N/A
Recruiting NCT02643173 - Hepatocellular Carcinoma Recurrence and Anesthesia N/A
Active, not recruiting NCT02525380 - Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma Phase 4
Active, not recruiting NCT02534337 - Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma Phase 2/Phase 3
Active, not recruiting NCT02527772 - Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma Phase 2/Phase 3
Terminated NCT02549755 - 11C-acetate for Treatment Response After Radiotherapy for HCC Phase 2
Recruiting NCT02243384 - Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma N/A
Recruiting NCT02174549 - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Phase 1/Phase 2
Recruiting NCT02128958 - Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Phase 2
Recruiting NCT01906216 - Sorafenib Chemoembolization Evaluation Controlled Trial Phase 2/Phase 3
Withdrawn NCT01956864 - Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer Phase 1
Completed NCT02156700 - Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors N/A
Enrolling by invitation NCT01715402 - Optimization of Health Expenditure in Liver Surgery N/A
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3